Boehringer Ingelheim's JASCAYD® Gains Japan Approval, Expanding IPF/PPF Treatment Reach
Event summary
- Japan’s MHLW approved JASCAYD® (nerandomilast) for IPF and PPF, making it the fourth market after the US, China, and UAE.
- The approval is based on Phase III FIBRONEER™ trials showing slowed lung function decline in IPF and PPF patients.
- JASCAYD® is the first oral PDE4B inhibitor with antifibrotic and immunomodulatory effects approved for these indications.
- Boehringer Ingelheim estimates 10,000–30,000 IPF patients in Japan, with no national estimates for PPF.
- Regulatory submissions for nerandomilast are under review in the EU, UK, and other countries, with additional approvals anticipated in 2026.
The big picture
Boehringer Ingelheim’s JASCAYD® approval in Japan marks a significant milestone in the treatment of IPF and PPF, conditions with high unmet medical need and limited therapeutic options. The approval follows successful Phase III trials and positions Boehringer Ingelheim to compete in a market where existing treatments often lead to discontinuation due to side effects. With regulatory submissions pending in other regions, the company is poised to expand its global footprint in pulmonary fibrosis treatments.
What we're watching
- Regulatory Momentum
- Whether Boehringer Ingelheim can secure additional approvals in the EU, UK, and other markets by the end of 2026.
- Market Penetration
- The pace at which JASCAYD® gains adoption in Japan, particularly among patients who previously discontinued other treatments due to side effects.
- Pipeline Expansion
- How Boehringer Ingelheim’s exploration of nerandomilast in systemic sclerosis (SSc) and myositis (IIM) progresses, potentially broadening its therapeutic reach.
Related topics